H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Celldex (NASDAQ: CLDX) today and set a price target of $2.15. The company’s shares opened today at $0.70, close to its 52-week low of $0.65.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.8% and a 39.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.26 and a one-year low of $0.65. Currently, Celldex has an average volume of 2.94M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company’s drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.
Read More on CLDX:
